Clinical Trial

Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 9, 2025 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2020-01-14; most recent amendment 2026-06-02.
Status change: Active, Not Recruiting → Completed 2025-12-19
Status change: Recruiting → Active, Not Recruiting 2025-01-07
Status change: Active, Not Recruiting → Recruiting 2024-07-15
Status change: Recruiting → Active, Not Recruiting 2022-09-29
Status change: Not Yet Recruiting → Recruiting 2020-06-12
Trial Details
NCT Number NCT04230499
Lead Sponsor Rapamycin Holdings Inc.
Collaborators: Cancer Insight, LLC, Biodexa Pharmaceuticals
Conditions Familial Adenomatous Polyposis
Enrollment 30 participants
Start Date 2021-01-18
Primary Completion 2025-03 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2025-01-09